Bone Non Current Liabilities Total vs Total Liab Analysis

BBLG Stock

USD 1.52 0.30 16.48%

Bone Biologics financial indicator trend analysis is way more than just evaluating Bone Biologics Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bone Biologics Corp is a good investment. Please check the relationship between Bone Biologics Non Current Liabilities Total and its Total Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Non Current Liabilities Total vs Total Liab

Non Current Liabilities Total vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bone Biologics Corp Non Current Liabilities Total account and Total Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between Bone Biologics' Non Current Liabilities Total and Total Liab is 0.72. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Total Liab in the same time period over historical financial statements of Bone Biologics Corp, assuming nothing else is changed. The correlation between historical values of Bone Biologics' Non Current Liabilities Total and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Bone Biologics Corp are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Non Current Liabilities Total i.e., Bone Biologics' Non Current Liabilities Total and Total Liab go up and down completely randomly.

Correlation Coefficient

0.72

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Non Current Liabilities Total

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Bone Biologics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bone Biologics Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

At this time, Bone Biologics' Enterprise Value Over EBITDA is most likely to increase significantly in the upcoming years. The Bone Biologics' current Enterprise Value Multiple is estimated to increase to 0.20, while Selling General Administrative is projected to decrease to roughly 2 M.

Bone Biologics fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Net Debt	Cash	Cash And Short Term Investments	Total Current Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Other Stockholder Equity	Total Liab	Common Stock	Short Long Term Debt Total	Other Current Assets	Short Term Debt	Net Tangible Assets	Accounts Payable	Long Term Debt	Net Receivables	Non Current Liabilities Total	Inventory	Short Long Term Debt	Property Plant Equipment	Current Deferred Revenue	Net Invested Capital
Common Stock Shares Outstanding		-0.39	-0.21	-0.36	-0.42	-0.39	-0.49	-0.34	0.24	0.67	-0.63	-0.51	-0.56	-0.74	-0.39	-0.33	-0.02	-0.2	-0.42	-0.52	-0.08	0.66	-0.15	0.67	-0.51	-0.23
Total Assets	-0.39		-0.65	0.99	0.76	1.0	0.65	-0.11	0.62	-0.45	0.59	-0.25	-0.07	0.55	0.67	-0.24	0.72	-0.27	0.44	0.32	-0.57	-0.45	0.39	-0.35	0.38	0.9
Net Debt	-0.21	-0.65		-0.68	-0.34	-0.66	-0.18	0.56	-0.99	-0.02	-0.12	0.89	0.73	0.08	-0.43	0.7	-0.93	0.34	-0.23	0.18	0.81	-0.06	-0.23	-0.14	0.03	-0.8
Cash	-0.36	0.99	-0.68		0.78	0.99	0.66	-0.12	0.64	-0.47	0.62	-0.29	-0.11	0.55	0.7	-0.23	0.73	-0.29	0.46	0.39	-0.57	-0.47	0.44	-0.38	0.43	0.94
Cash And Short Term Investments	-0.42	0.76	-0.34	0.78		0.76	0.71	0.39	0.28	-0.57	0.66	0.04	0.05	0.66	0.92	0.16	0.4	0.19	0.58	0.54	-0.16	-0.62	0.58	-0.48	0.56	0.64
Total Current Assets	-0.39	1.0	-0.66	0.99	0.76		0.65	-0.11	0.62	-0.45	0.59	-0.25	-0.07	0.55	0.67	-0.24	0.72	-0.27	0.44	0.32	-0.57	-0.45	0.39	-0.35	0.38	0.9
Other Current Liab	-0.49	0.65	-0.18	0.66	0.71	0.65		0.21	0.08	-0.52	0.6	0.22	0.41	0.57	0.6	0.0	0.18	0.02	0.43	0.47	-0.02	-0.7	0.07	-0.59	0.35	0.56
Total Current Liabilities	-0.34	-0.11	0.56	-0.12	0.39	-0.11	0.21		-0.6	-0.32	0.24	0.68	0.46	0.38	0.28	0.71	-0.48	0.52	-0.06	0.41	0.31	-0.31	0.16	-0.34	0.32	-0.31
Total Stockholder Equity	0.24	0.62	-0.99	0.64	0.28	0.62	0.08	-0.6		0.07	0.06	-0.92	-0.77	-0.13	0.37	-0.7	0.93	-0.36	0.19	-0.23	-0.82	0.13	0.23	0.2	-0.07	0.77
Retained Earnings	0.67	-0.45	-0.02	-0.47	-0.57	-0.45	-0.52	-0.32	0.07		-0.96	-0.35	-0.33	-0.93	-0.71	-0.39	-0.24	-0.3	-0.76	-0.83	0.05	0.94	-0.5	0.97	-0.89	-0.46
Other Stockholder Equity	-0.63	0.59	-0.12	0.62	0.66	0.59	0.6	0.24	0.06	-0.96		0.23	0.26	0.93	0.74	0.3	0.33	0.22	0.73	0.84	-0.14	-0.92	0.6	-0.92	0.91	0.61
Total Liab	-0.51	-0.25	0.89	-0.29	0.04	-0.25	0.22	0.68	-0.92	-0.35	0.23		0.91	0.45	-0.09	0.74	-0.76	0.32	0.02	0.45	0.72	-0.4	-0.09	-0.45	0.29	-0.49
Common Stock	-0.56	-0.07	0.73	-0.11	0.05	-0.07	0.41	0.46	-0.77	-0.33	0.26	0.91		0.43	-0.12	0.44	-0.63	0.18	0.0	0.44	0.6	-0.4	-0.27	-0.48	0.23	-0.3
Short Long Term Debt Total	-0.74	0.55	0.08	0.55	0.66	0.55	0.57	0.38	-0.13	-0.93	0.93	0.45	0.43		0.69	0.46	0.18	0.29	0.71	0.78	0.03	-0.9	0.55	-0.88	0.84	0.44
Other Current Assets	-0.39	0.67	-0.43	0.7	0.92	0.67	0.6	0.28	0.37	-0.71	0.74	-0.09	-0.12	0.69		0.09	0.55	0.33	0.77	0.54	-0.25	-0.71	0.61	-0.59	0.63	0.66
Short Term Debt	-0.33	-0.24	0.7	-0.23	0.16	-0.24	0.0	0.71	-0.7	-0.39	0.3	0.74	0.44	0.46	0.09		-0.58	0.21	0.11	0.55	0.53	-0.42	0.41	-0.39	0.47	-0.34
Net Tangible Assets	-0.02	0.72	-0.93	0.73	0.4	0.72	0.18	-0.48	0.93	-0.24	0.33	-0.76	-0.63	0.18	0.55	-0.58		-0.18	0.44	-0.06	-0.83	-0.15	0.31	-0.09	0.15	0.83
Accounts Payable	-0.2	-0.27	0.34	-0.29	0.19	-0.27	0.02	0.52	-0.36	-0.3	0.22	0.32	0.18	0.29	0.33	0.21	-0.18		0.31	0.09	0.33	-0.25	0.07	-0.29	0.22	-0.33
Long Term Debt	-0.42	0.44	-0.23	0.46	0.58	0.44	0.43	-0.06	0.19	-0.76	0.73	0.02	0.0	0.71	0.77	0.11	0.44	0.31		0.51	0.07	-0.77	0.53	-0.67	0.63	0.47
Net Receivables	-0.52	0.32	0.18	0.39	0.54	0.32	0.47	0.41	-0.23	-0.83	0.84	0.45	0.44	0.78	0.54	0.55	-0.06	0.09	0.51		0.15	-0.8	0.57	-0.84	0.91	0.36
Non Current Liabilities Total	-0.08	-0.57	0.81	-0.57	-0.16	-0.57	-0.02	0.31	-0.82	0.05	-0.14	0.72	0.6	0.03	-0.25	0.53	-0.83	0.33	0.07	0.15		-0.1	-0.12	-0.06	0.0	-0.69
Inventory	0.66	-0.45	-0.06	-0.47	-0.62	-0.45	-0.7	-0.31	0.13	0.94	-0.92	-0.4	-0.4	-0.9	-0.71	-0.42	-0.15	-0.25	-0.77	-0.8	-0.1		-0.46	0.95	-0.82	-0.45
Short Long Term Debt	-0.15	0.39	-0.23	0.44	0.58	0.39	0.07	0.16	0.23	-0.5	0.6	-0.09	-0.27	0.55	0.61	0.41	0.31	0.07	0.53	0.57	-0.12	-0.46		-0.33	0.75	0.44
Property Plant Equipment	0.67	-0.35	-0.14	-0.38	-0.48	-0.35	-0.59	-0.34	0.2	0.97	-0.92	-0.45	-0.48	-0.88	-0.59	-0.39	-0.09	-0.29	-0.67	-0.84	-0.06	0.95	-0.33		-0.82	-0.37
Current Deferred Revenue	-0.51	0.38	0.03	0.43	0.56	0.38	0.35	0.32	-0.07	-0.89	0.91	0.29	0.23	0.84	0.63	0.47	0.15	0.22	0.63	0.91	0.0	-0.82	0.75	-0.82		0.43
Net Invested Capital	-0.23	0.9	-0.8	0.94	0.64	0.9	0.56	-0.31	0.77	-0.46	0.61	-0.49	-0.3	0.44	0.66	-0.34	0.83	-0.33	0.47	0.36	-0.69	-0.45	0.44	-0.37	0.43

Click cells to compare fundamentals

Bone Biologics Account Relationship Matchups

Bone Biologics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	12.2K	12.1K	18.9K	47.6K	263.1K	250.0K
Total Assets	30.8K	0.0	6.7M	8.5M	3.7M	2.3M
Net Debt	11.3M	11.7M	(6.7M)	(7.5M)	(3.0M)	(2.9M)
Cash	24.1K	0.0	6.7M	7.5M	3.0M	2.0M
Cash And Short Term Investments	955.4K	24.1K	6.7M	7.5M	3.0M	2.1M
Liabilities And Stockholders Equity	1.0M	30.8K	6.7M	8.5M	3.7M	2.5M
Total Current Assets	30.8K	0.0	6.7M	8.5M	3.7M	2.3M
Other Current Liab	513.7K	535.6K	1.5M	2.5M	470.7K	447.2K
Total Current Liabilities	578.4K	13.7M	99.9K	2.5M	831.4K	789.8K
Total Stockholder Equity	(11.9M)	(13.7M)	6.6M	5.9M	2.9M	3.1M
Retained Earnings	(67.0M)	(68.9M)	(70.5M)	(72.0M)	(80.9M)	(76.9M)
Total Liab	11.9M	13.7M	99.9K	2.5M	831.4K	789.8K
Short Long Term Debt Total	8.2M	9M	11.3M	11.7M	13.5M	8.3M
Other Current Assets	105.2K	85.3K	6.7K	956.9K	711.2K	746.8K
Net Tangible Assets	(8.6M)	(11.9M)	(13.7M)	6.6M	7.6M	7.9M
Accounts Payable	42.9K	465.4K	99.9K	888.46	360.7K	202.9K
Non Current Liabilities Total	8.2M	0.0	11.3M	12.2M	99.9K	888.46
Net Invested Capital	(547.6K)	(2.0M)	6.6M	5.9M	2.9M	2.1M
Net Working Capital	(547.6K)	(13.7M)	6.6M	5.9M	2.9M	3.1M

Currently Active Assets on Macroaxis

VWITX	Vanguard Intermediate Term Tax Exempt
VGSTX	Vanguard Star Fund
VFIAX	Vanguard 500 Index
VTCLX	Vanguard Tax Managed Capital
VTSAX	Vanguard Total Stock

When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:

How To Invest In Bone

Details

Is Bone Stock a good investment?

Details

What is Bone Biologics' Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bone Biologics Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Complementary Tools for Bone Stock analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.

	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities

Is Bone Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(34.01)

Return On Assets

(0.85)

Return On Equity

(1.89)

The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bone Non Current Liabilities Total vs Total Liab Analysis

Non Current Liabilities Total vs Total Liab

Non Current Liabilities Total vs Total Liab Correlation Analysis

Correlation Coefficient

Non Current Liabilities Total

Total Liab

Bone Biologics fundamental ratios Correlations

Bone Biologics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bone Biologics fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Bone Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash
Property Plant Equipment	+ 0.97	Retained Earnings
Property Plant Equipment	+ 0.95	Inventory
Net Invested Capital	+ 0.94	Cash

Total Stockholder Equity	- 0.99	Net Debt
Other Stockholder Equity	- 0.96	Retained Earnings
Short Long Term Debt Total	- 0.93	Retained Earnings
Net Tangible Assets	- 0.93	Net Debt
Property Plant Equipment	- 0.92	Other Stockholder Equity
Inventory	- 0.92	Other Stockholder Equity